We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
EKF Introduces Novel Molecular Transport Media for Dual COVID-19 and Influenza Sampling
Product News

EKF Introduces Novel Molecular Transport Media for Dual COVID-19 and Influenza Sampling

EKF Introduces Novel Molecular Transport Media for Dual COVID-19 and Influenza Sampling
Product News

EKF Introduces Novel Molecular Transport Media for Dual COVID-19 and Influenza Sampling


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "EKF Introduces Novel Molecular Transport Media for Dual COVID-19 and Influenza Sampling"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

EKF Diagnostics, the global in vitro diagnostics company, has announced that it has added a novel viral transport media for the safe sample handling and testing of multiple infectious diseases from a single swab to its product range. PrimeStore® MTM (Molecular Transport Medium) is an FDA cleared and CE IVD marked sample collection device which deactivates viruses, including COVID-19, flu A, flu B, HIV and TB. Already proven in the U.S. market, this fully patented device ensures transportation and workplace safety for disease testing programs, greatly reducing risk of infection to health workers, couriers, and lab technicians.

Traditional viral transport media (VTM) were designed for transporting live samples to be cultured and also contain ingredients that inhibit optimal molecular testing. However, modern molecular tests do not require viable virus, but just intact microbial nucleic acids. Molecular testing is now widespread due to its improved performance and turnaround times compared to traditional microbiology testing. In fact, most currently approved tests for COVID-19 and other infectious diseases are nucleic acid based molecular assays, so removing the need for and risk of live pathogen transportation for routine testing.

Designed and optimized for molecular testing, PrimeStore MTM is a unique FDA class 2 cleared sample collection and transportation device that effectively kills viral and bacterial pathogens whilst preserving and stabilizing the released DNA and RNA. The molecular transport media supports many downstream molecular applications, including qPCR and next generation sequencing. The sample can be safely stored at ambient temperature for up to 7 days and re-used several times. As well as reducing the risks of handling live pathogenic samples, this also cuts costs by eliminating cold chain requirement and need for Category 3 facilities, as testing can take place outside of containment.

As multiple tests can be processed from one sample swab, this makes it ideal for the approaching flu season since samples stored in PrimeStore MTM can be tested for both COVID-19 and influenza from a single sample that has been inactivated and stabilized. This can assist with disease differentiation at reduced costs.

Advertisement